Divalproex Sodium (Discription01)
Divalproex Sodium
Product Images NDC 55648-724
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55648-724). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Wockhardt Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
100 Tablets Container Label (Divalproex Sodium Er Tablets 250 mg 100 Tablets Label)
This is a container label for Divalproex Sodium Extended-Release Tablets with 250mg strength per tablet. Each tablet contains Divalproex and sodium equivalent to valproic acid. It also includes manufacturer and distributor information, as well as instructions not to accept the bottle if the seal is broken. The label advises dispensing in a USP tight, light-resistant container and the pharmacist should provide a Patient Information Sheet. There is an enclosure with prescribing information. Size of the label is 105mm x 45mm.*
100 Tablets Container Label (Divalproex Sodium Er Tablets 500 mg 100 Tablets Label)
This is a container label for Divalproex Sodium Extended-Release Tablets, containing 100 tablets of 500 mg each. It includes important product information such as the drug's active ingredient and equivalent amount, as well as pharmaceutical prescribing and dispensary instructions. The label also displays a warning not to use the product if the seal is broken or missing. The product should be dispensed in a USP tight, light-resistant container. The label includes the manufacturer's contact details, and its size is 115mm x 55mm.*
Figure 1 (Figure01)
The text is describing a chart showing the percentage reduction in CPS (cycles per second) rate for patients taking divalproex sodium delayed-release tablets compared to a placebo. The chart also includes the percentage of patients who showed improvement, no change, or worsening in their CPS rate.*
Figure 2 (Figure02)
This text appears to be a graph showing the percentage of patients who experienced a reduction in CPS Ratk with high dose and low dose divalproex sodium delayed-release tablets. The graph indicates that 50% of patients experienced improvement while the remaining patients experienced either no improvement or worsening. There is not enough information to determine the context (e.g. what CPS Ratk is, what condition the tablets are treating, etc.).*
Figure 3 (Figure03)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
